Details

Autor(en) / Beteiligte

• Lonn, Eva M
• Bosch, Jackie
• López-Jaramillo, Patricio
• Zhu, Jun
• Liu, Lisheng
• Pais, Prem
• Diaz, Rafael
• Xavier, Denis
• Sliwa, Karen
• Dans, Antonio
• Avezum, Alvaro
• Piegas, Leopoldo S
• Keltai, Katalin
• Keltai, Matyas
• Chazova, Irina
• Peters, Ron J.G
• Held, Claes
• Yusoff, Khalid
• Lewis, Basil S
• Jansky, Petr
• Parkhomenko, Alexander
• Khunti, Kamlesh
• Toff, William D
• Reid, Christopher M
• Varigos, John
• Leiter, Lawrence A
• Molina, Dora I
• McKelvie, Robert
• Pogue, Janice
• Wilkinson, Joanne
• Jung, Hyejung
• Dagenais, Gilles
• Yusuf, Salim

Titel

Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease

Ist Teil von

• The New England journal of medicine, 2016-05, Vol.374 (21), p.2009-2020

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2016

Quelle

MEDLINE

Beschreibungen/Notizen

• In one comparison from a 2-by-2 factorial trial, over 12,000 participants with a mean baseline blood pressure of 138/82 mm Hg were assigned to candesartan plus hydrochlorothiazide or to placebo. At 5.6 years, there was no between-group difference in the rates of cardiovascular events. High blood pressure is the leading risk factor for cardiovascular disease globally 1 and affects more than 1 billion adults worldwide. 2 Observational studies involving persons without cardiovascular disease show a graded increase in risk at systolic blood-pressure levels above 115 mm Hg. 3 It has been suggested that lowering blood pressure at any level above this value will reduce the risk of cardiovascular events. 4 Antihypertensive therapy has been clearly shown to reduce the risk of cardiovascular disease among people with vascular or renal disease, diabetes, or hypertension with end-organ damage or, in the absence of these conditions, among persons with a systolic . . .